Demographic details and tumour staging of the patients in the study
| Placebo | Ranitidine | Total | |
| Number of patients | 110 | 112 | 222 |
| Number of men (%) | 76 (69) | 80 (71) | 156 (70) |
| Mean (range) age (years) | 69.6 (38–88) | 68.1 (46–89) | 68.8 (38–89) |
| Mean (range) weight (kg) | 64.7 (44.5–101.5) | 67.3 (31.8–105.0) | 66.0 (31.8–105.0) |
| 30 day mortality (%) | 21 (19) | 15 (13) | 36 (16) |
| Tumour stage1-150(%) | |||
| I | 5 (5) | 7 (7) | 12 (6) |
| II | 17 (16) | 23 (22) | 40 (19) |
| III | 46 (42) | 41 (38) | 87 (40) |
| IVa | 17 (16) | 17 (16) | 34 (16) |
| IVb | 24 (22) | 19 (18) | 43 (20) |
↵1-150 In six cases (one placebo, five ranitidine) the staging was incomplete.